NICE is unable to make a recommendation about the use in the NHS of teduglutide for treating short bowel syndrome because Takeda withdrew its evidence submission. Another company has taken over the rights to teduglutide and has confirmed that it wishes to make a new submission for the appraisal. This will be scheduled into NICE's work programme.
If NHS organisations wish to consider teduglutide for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.